Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anixa Biosciences

2.73
+0.01000.37%
Volume:46.73K
Turnover:129.18K
Market Cap:87.89M
PE:-6.94
High:2.80
Open:2.79
Low:2.72
Close:2.72
Loading ...

BEAM Down Despite Positive Initial Data From Genetic Disorder Study

Zacks
·
12 Mar

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

Zacks
·
10 Mar

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

PR Newswire
·
10 Mar

Anixa Biosciences Announces Chief Development Officer DR. PAM Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19TH

THOMSON REUTERS
·
03 Mar

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

PR Newswire
·
03 Mar

Anixa doses first patient in third cohort of Phase 1 clinical trial of CAR-T

TIPRANKS
·
26 Feb

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

THOMSON REUTERS
·
26 Feb

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

PR Newswire
·
26 Feb

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

PR Newswire
·
25 Feb

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

PR Newswire
·
24 Feb

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Zacks
·
21 Feb

Anixa Biosciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Feb

H.C. Wainwright Sticks to Its Buy Rating for Anixa Biosciences (ANIX)

TIPRANKS
·
19 Feb

Anixa Biosciences: Advancing CAR-T Therapy and Cancer Vaccines with Strategic Trial Amendments and Robust Financial Position

TIPRANKS
·
19 Feb

Anixa Biosciences announces approval of protocol amendment for CAR-T trial

TIPRANKS
·
18 Feb

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

THOMSON REUTERS
·
18 Feb

Anixa Biosciences Inc - Amendment Allows Second Dose and Expands Eligibility in CAR-T Trial

THOMSON REUTERS
·
18 Feb

Director Shows Confidence in Anixa Biosciences with New Stock Purchase

TIPRANKS
·
30 Jan

Anixa Biosciences Inc: With $20 Mln in Cash and Investments, We Have a Cash Runway of Over 2.5 Years

THOMSON REUTERS
·
21 Jan

Anixa Biosciences Leads 3 Promising Penny Stocks On US Exchanges

Simply Wall St.
·
17 Jan